Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanostart subsidiary MagForce: Patient recruitment for phase II clinical trials for Nano-Cancer® therapy successfully completed

Abstract:
* Critical milestone achieved toward successful conclusion of phase II clinical trials
* Application for regulatory approval of Nano-Cancer® therapy later this year
* Sales and marketing within European Union expected to begin in 2010

Nanostart subsidiary MagForce: Patient recruitment for phase II clinical trials for Nano-Cancer® therapy successfully completed

Frankfurt / Berlin | Posted on September 23rd, 2009

MagForce Nanotechnologies AG, a majority-owned subsidiary of Nanostart AG, has recruited the last remaining patients into the ongoing phase II clinical trials to demonstrate the efficacy of its proprietary Nano-Cancer® therapy in cases of recurrent glioblastoma. With this milestone, the necessary number of patients for statistical evaluation has been attained, marking the last key prerequisite to successfully conclude these clinical trials and proceed to regulatory approval.

Glioblastoma is the most commonly occurring type of malignant brain tumor in adults. The results of these phase II clinical trials will serve as the basis for the conformity evaluation procedure required under the German Medical Devices Act (Medizinproduktegesetz). This procedure qualifies medical devices for CE marking, which certifies conformity with health and safety regulations throughout the European Economic Area. MagForce hopes to establish its new therapy, which is virtually free of patient side effects, as a fourth pillar alongside the existing standard cancer treatment methods: surgery, radiation and chemotherapy.

"We plan on preparing the statistical data in the fourth quarter of 2009, as soon as enough patients have concluded the post-observation period or have otherwise reached the study endpoint, so that we will be able to have the product file put together before the end of this year. Once we have received the CE marking, we hope to be in a position already next year to commence marketing of Nano-Cancer® therapy throughout Europe," said Dr. Uwe Maschek, CEO of MagForce Nanotechnologies AG.

Marco Beckmann, CEO of Nanostart AG, added that "we are watching with great excitement as regulatory approval for the unique Nano-Cancer® therapy from our subsidiary MagForce Nanotechnologies gets closer and closer. The completion of patient recruitment marks one of the final milestones toward this goal."

Nanostart AG, the leading nanotechnology investment company, owns 77 percent of the shares of the Berlin-based cancer research company.

For further information about MagForce and its Nano-Cancer® therapy, visit //www.nanostart.de/en/portfoliodivision/portfolio/magforcenanotechnologiesag/1973..html

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

####

About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.

About MagForce Nanotechnologies AG

MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors. www.magforce.com

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122


Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Possible Futures

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Researchers discern the shapes of high-order Brownian motions November 17th, 2014

VDMA Electronics Production Equipment: Growth track for 2014 and 2015 confirmed: Business climate survey shows robust industry sector November 14th, 2014

Open Materials Development Will Be Key for HP's Success in 3D Printing: HP can make a big splash in 3D printing, but it needs to shore up technology claims and avoid the temptation of the razor/razor blade business model in order to flourish November 11th, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

Announcements

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Nanobiotechnology

Scientists trace nanoparticles from plants to caterpillars: Rice University study examines how nanoparticles behave in food chain December 16th, 2014

FEI and Oregon Health & Science University Install a Complete Correlative Microscopy Workflow in Newly Built Collaborative Science Facility December 16th, 2014

UCLA engineers first to detect and measure individual DNA molecules using smartphone microscope December 15th, 2014

Biomimetic dew harvesters: Understanding how a desert beetle harvests water from dew could improve drinking water collection in dew condensers December 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE